Vincenzo Minotti

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola et al. · Journal of Thoracic Oncology · 2011 · 176 citations · Full text

Kras Mutations, Medicine, Receptor Tyrosine Kinase +8

Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

Piero Ferollà, Maria Pia Brizzi, Tim Meyer et al. · The Lancet Oncology · 2017 · 134 citations

Long-acting Pasireotide, Oncology, Medicine +10

Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype

Giulio Metro, Rita Chiari, Simona Duranti et al. · Lung Cancer · 2012 · 69 citations

Clinical Outcome, Specific Mutant Kras, Medicine +10

Concomitant chemoradiation (CRT) or cetuximab/RT (CET/RT) versus induction Docetaxel/ Cisplatin/5-Fluorouracil (TPF) followed by CRT or CET/RT in patients with Locally Advanced Squamous Cell Carcinoma of Head and Neck (LASCCHN). A randomized phase III factorial study (NCT01086826).

Maria Grazia Ghi, Adriano Paccagnella, Daris Ferrari et al. · Journal of Clinical Oncology · 2014 · 66 citations

Surgical Oncology, Induction Tpf, Pharmacotherapy +16

Association of Cytidine Deaminase and Xeroderma Pigmentosum Group D Polymorphisms with Response, Toxicity, and Survival in Cisplatin/Gemcitabine-Treated Advanced Non-small Cell Lung Cancer Patients

Vienna Ludovini, Irene Floriani, Lorenza Pistola et al. · Journal of Thoracic Oncology · 2011 · 59 citations

Cytidine Deaminase, Oncogenic Agent, Medicine +8